IOVANCE BIOTHERAPEUTICS (IOVA) director receives 90,316 deferred stock units

Rhea-AI Filing Summary

Countouriotis Athena reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. director Athena Countouriotis received a grant of 90,316 deferred restricted stock units (DRSUs) linked to common stock, awarded at no cash cost under the company’s 2018 Equity Incentive Plan.

The DRSUs vest if she continues providing service and will vest on the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, delivery of common shares is deferred until specific events such as board service ending, a qualifying change in control, or ten years after the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Countouriotis Athena

Role null

Type	Security	Shares	Price	Value
Grant/Award	Deferred Restricted Stock Unit	90,316	$0.00	--

Holdings After Transaction: Deferred Restricted Stock Unit — 90,316 shares (Direct, null)

Footnotes (1)

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Key Figures

DRSUs granted: 90,316 units Exercise/Conversion price: $0.00 per unit Underlying common shares: 90,316 shares +1 more

4 metrics

DRSUs granted 90,316 units Deferred restricted stock units awarded to director

Exercise/Conversion price $0.00 per unit Stated price for DRSU grant

Underlying common shares 90,316 shares Each DRSU equals one common share

Post-transaction DRSU holdings 90,316 units Total deferred RSUs following transaction

Key Terms

Deferred Restricted Stock Unit, 2018 Equity Incentive Plan, annual shareholder meeting, change in control

4 terms

Deferred Restricted Stock Unit financial

"Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share..."

2018 Equity Incentive Plan financial

"…granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."

annual shareholder meeting financial

"…vest on the earlier of: (i) the first anniversary... or (ii) the day prior to the Issuer's next annual shareholder meeting."

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

change in control financial

"…(ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 05:16 PM Accepted by SEC EDGAR 06/18/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Countouriotis Athena

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Restricted Stock Unit	(1)	06/16/2026		A		90,316		(2)	(2)	Common Stock	90,316	$0	90,316	D

Explanation of Responses:

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

	/s/ Athena Countouriotis	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Athena Countouriotis?

IOVANCE BIOTHERAPEUTICS reported that director Athena Countouriotis received 90,316 deferred restricted stock units. These units are a stock-based compensation award tied to the company’s common stock rather than an open-market share purchase or sale.

How many IOVA deferred restricted stock units were granted in this Form 4 filing?

The filing shows a grant of 90,316 deferred restricted stock units. Each unit represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock, subject to vesting and later settlement conditions described in the award terms.

What are deferred restricted stock units (DRSUs) in the IOVA Form 4?

Deferred restricted stock units are rights to receive common shares in the future rather than immediately. For IOVA, each DRSU equals one share, subject to service-based vesting and later delivery events such as board departure, change in control, or a ten-year long-stop date.

When do Athena Countouriotis’s IOVA DRSUs vest according to the filing?

The DRSUs vest if she continues serving the company and will vest on the earlier of the first anniversary of the grant date or the day before IOVANCE BIOTHERAPEUTICS’ next annual shareholder meeting, whichever comes first under the plan terms.

When will IOVANCE BIOTHERAPEUTICS common stock be issued for these DRSUs?

Common stock for the DRSUs is issued only after certain events. Shares are delivered after board resignation, removal, death, disability, a qualifying change in control, or ten years from the grant date, whichever occurs earliest under the agreement.

Is this IOVA Form 4 transaction an open-market buy or sell of shares?

No, this Form 4 reflects a compensation-related grant, not an open-market trade. The director acquired 90,316 deferred restricted stock units at a stated price of zero under IOVANCE BIOTHERAPEUTICS’ 2018 Equity Incentive Plan.